|
|
Rotavirus
|
| Clinical phase 3 |
Lanzhou lamb rotavirus reassortants; lamb rotavirus-based reassortants carrying human rotavirus antigens; and G2 to G4 specificity |
Oral (live attenuated) |
Lanzhou Institute of Biological Products, Lanzhou, China |
| Clinical phase 3 |
RotaShield; rhesus-human reassortant strains and tetravalent; and G1 to G4 specificity |
Oral (live attenuated) |
International Medica Foundation, Rochester, MN, USA |
| Clinical phase 3 |
UK-BRV tetravalent; and G1 to G4 specificity |
Oral (live attenuated) |
Shantha Biotech, Hyderabad, India |
| Clinical phase 2b |
RV3 neonatal strain; and G3P6 specificity |
Oral (live attenuated) |
Murdoch Children’s Research Institute, Parkville, VIC, Australia and PT Biofarma, Bandung, Indonesia |
| Clinical phase 2 |
Subunit; truncated VP4 protein; and P4, P6, and P8 specificity |
Intramuscular (subunit) |
PATH, Seattle, WA, USA |
| Clinical phase 1 |
UK-BRV reassortant; and G1 to G4, and G9 specificity |
Oral (live attenuated) |
Instituto Butantan, Sao Paulo, Brazil |
| Clinical phase 1 |
UK-BRV reassortant; and G1 to G4, G8, and G9 specificity |
Oral (live attenuated) |
Wuhan Institute of Biological Products, Wuhan, China and PATH, Seattle, WA, USA |
|
Norovirus
|
| Clinical phase 2b |
Norovirus virus-like particles; and GI.1 and GII.4 |
Intramuscular |
Takeda Vaccines, Cambridge, MA, USA |
| Clinical phase 1 |
Recombinant adenovirus expressing norovirus VP1; and GI.l |
Oral |
Vaxart, San Fransisco, CA, USA |
